ACADIA Pharmaceuticals Inc. (ACAD)

28.05
NASDAQ : Health Technology
Prev Close 29.21
Day Low/High 27.90 / 29.62
52 Wk Low/High 13.17 / 30.38
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 144.49M
Market Cap 4.22B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD)

Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

ACADIA Pharmaceuticals Appoints Jim Daly To Board Of Directors

ACADIA Pharmaceuticals Appoints Jim Daly To Board Of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference On January 12, 2016

ACADIA Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference On January 12, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Appoints Julian C. Baker To Board Of Directors

ACADIA Pharmaceuticals Appoints Julian C. Baker To Board Of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock

ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., As Executive Vice President, Head Of Research And Development

ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., As Executive Vice President, Head Of Research And Development

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., To Board Of Directors

ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., To Board Of Directors

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Unilever, Visa and NXP Semiconductors Are Superior Stocks, Says Mott Capital Manager

Unilever, Visa and NXP Semiconductors Are Superior Stocks, Says Mott Capital Manager

Unilever shares are up over 7% this year and the company should continue to perform well.

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Visa, Unilever and NXP Semi Are Superior Stocks Says Mott Manager

Unilever (UL) shares are up over 7% so far this year and the consumer staples giant will continue to perform well as it expands its reach in the emerging markets.

Weak On High Volume: ACADIA Pharmaceuticals (ACAD)

Weak On High Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a weak on high relative volume candidate

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Present At The 24th Annual Credit Suisse Healthcare Conference On November 10, 2015

ACADIA Pharmaceuticals To Present At The 24th Annual Credit Suisse Healthcare Conference On November 10, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

3 Stocks Spiking on Big Volume

3 Stocks Spiking on Big Volume

Here's a technical look at how to trade three stocks rising on unusual volume today.

ACADIA Pharmaceuticals Announces FDA Priority Review Of NUPLAZID™ (Pimavanserin) New Drug Application For Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Announces FDA Priority Review Of NUPLAZID™ (Pimavanserin) New Drug Application For Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals To Announce Third Quarter Financial Results On November 5, 2015

ACADIA Pharmaceuticals To Announce Third Quarter Financial Results On November 5, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Acadia's New Drug Could Have Potential for Investors

Acadia's New Drug Could Have Potential for Investors

Acadia Pharmaceuticals has been buffeted in recent months but its treatment for psyhosis related to Parkinson's disease has great potential.

Interesting ACAD Put And Call Options For November 20th

Interesting ACAD Put And Call Options For November 20th

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new November 20th contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29, 2015

ACADIA Pharmaceuticals To Present At The Ladenburg Thalmann 2015 Healthcare Conference On September 29, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Water-Logged And Getting Wetter: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Perilous Reversal Watch: ACADIA Pharmaceuticals (ACAD)

Perilous Reversal Watch: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

Acadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's Treatment

Acadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's Treatment

Acadia Pharmaceuticals (ACAD) shares are rising after the company submitted a new drug application for its Parkinson's related psychosis treatment.

Steve Davis, Chief Executive Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

Steve Davis, Chief Executive Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Submits New Drug Application For NUPLAZID™ For The Treatment Of Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Submits New Drug Application For NUPLAZID™ For The Treatment Of Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

The Trader Daily: Let's Welcome Biotechs to the House of Pain

The bulls can show them around the place.

TheStreet Quant Rating: D (Sell)